News

  • Announcing Exclusive Partnership with Espansione Group

    Aimed at Driving Disruptive Innovation in Eye Care and Beyond in South-East AsiaTopcon Singapore Medical (referred to as “Topcon” in this document for brevity’s sake) and Espansione Group announce today a long-term exclusive partnership for the South-East Asia region.Starting April 1, 2023, Topcon will be the official and sole distributor for the South East Asian region of Espansione Group’s full portfolio, including light-based technologies such as Light Modulation® Low-level Light Therapy (LM® LLLT), its signature photobiomodulation technology, and Optimal Power Energy® Intense Pulsed Light (OPE® IPL).“We’re thrilled to grow our relationship with Topcon even stronger, including the South-East Asian region to our global collaboration efforts” commented Matteo Corbellino, Chief Marketing & Innovation Officer at Espansione Group. “We found a true partner in Topcon with a highly engaged and capable team striving to always deliver an extremely high level of service. We both want to raise the bar in the dry eye field and beyond, and that’s where we’ve found alignment. We believe that this partnership will create a powerful synergy that will enable us to push the boundaries of what’s possible in ophthalmology and beyond—as our technologies gain momentum worldwide, APAC and SEA in particular will be increasingly relevant for us.” “It's been Topcon Asia leadership's vision to look for ground-breaking type of collaborations. Our chance to meet the Espansione executive team gave us the opportunity to turn this vision into a reality” said Leo Nagatake, Managing Director at Topcon. “We see this strategic alliance with Espansione paving the way for our privileged access into their range of highly innovative and forward-thinking treatment products and solutions complementing the comprehensive range of Topcon's diagnostic equipment such as our MYAH - the unique multifunctional instrument for the management of dry eye & myopia. This synergistic partnership will further expand our service spectrum enabling us to provide more wholistic solutions to our esteemed clientele; from pre-diagnosis towards effective dry eye treatment followed by post treatment follow ups that will eventually benefit our end patients with a comprehensive end to end experience.”Professionals are encouraged to contact Topcon to obtain details on the portfolio of solutions in light therapy and digital imaging showcased with this partnership, including eye-light® , meibomask®, my-mask® and me-check®.About Espansione GroupEspansione Group is an established player in the medtech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.   For more information, see www.espansionegroup.itAbout Topcon HealthcareTopcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground- breaking remote diagnostic technology.A globally-oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.For more information, see https://topconhealthcare.sgMedia ContactsEspansione GroupMatteo Corbellinomatteo.corbellino@espansione.itTopcon Singapore MedicalPatrick Foopfoo@topcon.com

  • Notice of Changes of President and CEO (Replacement of President)

    January 30, 2023Topcon Corporation (TSE: 7732) hereby announces that the change of President and CEO was resolved at a meeting of the board of directors held today. The appointments will take effect on April 1, 2023.Change of President and CEO(effective April 1, 2023)NameNew PositionCurrent PositionSatoshi HiranoRepresentative Director,ChairmanRepresentative Director,President & CEOTakashi EtoRepresentative Director,President & CEORepresentative Director,Executive Vice PresidentGeneral Manager, Quality Assurance Div.Takashi EtoTopcon Corporation, the parent company of all Topcon Healthcare companies, announced changes in their president and CEO position that will be effective with the new fiscal year. Takashi Eto will assume the position of Representative Director,  President and CEO, effective April 1, 2023. Current Topcon Corporation President and CEO Satoshi Hirano has served in the role since 2013 and will continue to contribute to the development of Topcon as Chairman of the Board, assisting and advising the new president.Read the news on the Topcon Corporation Website : link

  • Topcon Introduces NW500 Non-Mydriatic Retinal Camera

    TOKYO, JAPAN, OCTOBER 2022 – Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched the NW500, its new fully-automatic, non-mydriatic retinal camera that delivers reliable, sharp-quality imaging with enhanced capability.The NW500 offers innovative slit scan illumination and a rolling shutter mechanism, which helps to overcome one of the known causes of poorly graded images in its ability to effectively image smaller pupils, from 2.00mm or more*. A 12-megapixel sensor delivers excellent quality colour fundus images for clear review and analysis.The NW500 contributes to a streamlined workflow and enhanced patient experience by offering the ability to acquire retinal images in a lighted setting without the need to dilate patients. The NW500 offers excellent quality colour fundus images across the traditional 3 fixation points (Disc, Centre, and Macula), as well as the 9 fixation positions for peripheral photography.Touch-screen operation offers rapid, simple capture with just one touch. Fully-automated operation gives clinicians the flexibility to delegate screening to non-clinical staff. The improved processing speed** means it takes less time to capture images and gives operators the ability to increase patient throughput. A variety of connectivity options are available to suit the needs of clinical and screening businesses.“The NW500 reflects Topcon’s commitment to continuous innovation in pursuit of technology that helps to improve the quality-of-care patients receive and make care more efficient and accessible,” says Senior Director of Product Management, Tobias Kurzke. “Combined, the innovative slit scan technology and 12-megapixel camera offer clinicians fast, sharp quality imaging with less failure and retakes, making the process of acquiring fundus images faster and more reliable than before. The added benefit of enhancing the patient experience through faster screening times and the absence of the need for dilation will give clinicians and large volume wellness screening settings a competitive advantage.”Find out more about NW500https://topconhealthcare.sg/products/nw500/* Confirmed with model eye** As compared to the Topcon non-mydriatic retinal camera TRC-NW400Note: The information contained on this website is intended for healthcare professionals. Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.

  • Topcon Introduces SOLOS – Automatic Lens Analyzer

    APRIL, 2022 - Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, is pleased to announce that it has launched SOLOS, an automatic lens analyzer that enables advanced, accurate and efficient lens analysis at the touch of a button, to Asia Pacific region.SOLOS simplifies clinical workflow by combining a fully automated lensmeter with a full range spectrometer. The multi-functional device offers automatic lens type detection, automatic marking, and lens mapping of single vision, progressive and other multifocal lenses, whether glazed in a spectacle frame or as uncut lenses. With a single touch, SOLOS automatically positions each lens, detects the lens type and performs comprehensive measurements of both lenses within a spectacle frame.SOLOS features an extended measurement range of +/- 20D and a built-in spectral transmittance meter that measures UV, blue & visible light transmittance as well as lens tint. Results are displayed instantly and can be sent to an EMR or wirelessly transferred to Topcon’s CV-5000S or Chronos refraction system, enhancing connectivity, preventing transcription errors, and enabling seamless comparisons of new prescriptions with previous spectacles to support purchasing decisions.“SOLOS goes beyond conventional lensometry and continues in Topcon’s tradition of developing smart, efficient and multimodal technologies that enhance patient care. As the name implies, one device does it all, enabling eyecare practitioners to benefit from increased operational efficiencies while obtaining highly accurate and comprehensive lens measurement results. We are very pleased to bring this device to market,” stated Paul op den Kelder, Global Product Manager for Topcon Healthcare.Find out more about SOLOShttps://topconhealthcare.sg/products/solos/Note: The information contained on this website is intended for healthcare professionals. Not all products, services or offers are approved or offered in every market, and products vary from one country to another. Contact your local distributor for country-specific information and availability.

  • Topcon acquires VISIA Imaging S.r.l, ophthalmic medical device manufacturer in Italy

    Tokyo, Japan – July 6th, 2021 - Topcon Corporation announced that it has acquired VISIA Imaging S.r.l, an ophthalmic device manufacturer headquartered in suburban Florence, Italy.VISIA Imaging S.r.l (hereinafter “VISIA”), was established in 1993 and specializes in the design, development, and manufacturing of anterior segment (cornea, crystalline lens, etc.) examination hardware and software. This acquisition enhances Topcon’s development and manufacturing capabilities of anterior segment devices and software, which complements the company’s strong portfolio of fundus imaging devices that includes fundus cameras and optical coherence tomography (OCT). The acquisition further reinforces Topcon’s position as a leading ophthalmic diagnostic device manufacturer.For many years, Topcon has been a distributor of VISIA’s technology including the CC-100 series visual acuity charts (CC-100 series), the CA-800 topographer and corneal analyzer, the MYAH biometer and corneal topographer and the Aladdin biometer. “The integration of a Japanese company and an Italian company, both with strengths in optical design, mechanical engineering, and manufacturing of medical devices, will enhance the synergies between the two companies. Both VISIA and Topcon value true reliability and innovative technology, making two companies ideal partners. I am very excited to move forward in our business together to continue producing advanced technology that benefits both patients and eye care professionals.””- commented Fumio Ohue, Managing Executive Officer of Topcon Corporations.Major VISIA products:(from the left: ALADDIN, CA-800, CC-100, MYAH)The acquisition of VISIA will enable Topcon to create additional synergies within the company’s product portfolio, expand its product offering, strengthen the Topcon Healthcare brand, and continue to grow the business. Furthermore, the acquisition gives Topcon Healthcare additional product design and development capabilities that will accelerate product development and enable the company to better meet the needs of the market.“I am so pleased that VISIA Imaging is becoming part of Topcon Healthcare and very excited for the next chapter in our long relationship. VISIA Imaging is focused on development and manufacturing of HW/SW solutions for eye care with high expertise in anterior segment. I am confident to release new beautiful products to support Topcon to become a market leader in myopia management, and to increase Topcon’s presence in cataract surgery with Premium IOL calculation”- said Alessandro Foggi, CEO VISIA Imaging S.r.lVISIA’s product portfolio helps eye care professionals diagnose and manage a number of eye health conditions including myopia. In recent years, the increase in the number of patients at risk for myopic-related eye diseases has become a global issue, and Topcon is committed to working with eye care professionals to address this eye health problem. By integrating VISIA and its products into the Topcon Healthcare portfolio, the company is better equipped to develop myopia management solutions and strengthen collaborations with companies in the myopia treatment field.[Press release information in Europe]https://www.businesswire.com/news/home/20210714005887/en/Topcon-Healthcare-Acquires-VISIA-Imaging

  • Topcon Announces the Launch of Chronos

    It is time to reinvent refraction.Update January 28, 2021Topcon launches the revolutionary Chronos, Refraction System.Topcon, a leading provider of eye care devices and software solutions for the global eye care community, announced the launch of the revolutionary Refraction System, Chronos.Topcon Chronos offers binocular autorefraction, keratometry measurements and visual acuity with subjective testing. Chronos is the single space-saving instrument that optimizes the Eye Care Professionals’ workflow.SAVE SPACEChronos combines binocular autorefraction and keratometry measurements with binocular subjective testing and visual acuity in a single instrument that occupies minimum space.Chronos reduces the number of conventional refraction lanes and additional refractometers needed.GROWChronos offers the versatility critical for growing your practice.DELEGATESightPilot™ is a guided refraction system that simplifies the exam and facilitates delegation..list .wp-block-column { padding-left: 0;}.list .wp-block-column ul { padding-left: 20px;}.wp-block-columns+.wp-block-columns { margin-top: 20px;}@media (max-width: 781px) {.wp-block-columns+.wp-block-columns { margin-top: 40px;}}(press release information in Europe)https://kommunikasjon.ntb.no/pressemelding/topcon-announces-the-european-launch-of-chronos?publisherId=90063&releaseId=17896062(press release information in the U.S.)https://www.businesswire.com/news/home/20201113005598/en/Topcon-Announces-the-US-Launch-of-Chronos*About the Chronos, Refraction SystemAbout Topcon HealthcareTopcon Healthcare is a branded eyecare business of Topcon. Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions, including advanced multi-modal imaging, vendor-neutral data management, safe distancing, and ground-breaking remote diagnostic technology.

  • IDx and Topcon sign exclusive AI platform agreement for the U.S. market

    IDx, the company behind the first and only FDA-cleared autonomous AI diagnostic system, joins forces with Topcon, a pioneering ophthalmic device manufacturer, to tackle preventable blindnessUpdate October 23, 2018CORALVILLE, IA and OAKLAND, NJ, October 22, 2018 - IDx, a leading AI diagnostics company, and Topcon, one of the world’s leading ophthalmic device manufacturers, have signed an exclusivity agreement that will allow the companies to scale delivery of AI-based diagnostic solutions in the U.S. market.The agreement grants exclusive rights to IDx in the U.S. as the only autonomous AI company permitted to sell its products with the Topcon NW400 - an easy to use, robotic fundus camera. Topcon continues to collaborate with other partners in the AI space for solutions that fall outside of this autonomous agreement.In turn, IDx has agreed to assign Topcon’s NW400 as the only robotic desktop fundus camera with less than a 55 degree field of view to be integrated with IDx-DR, an autonomous AI system that instantly detects diabetic retinopathy in fundus images.“The importance of ease of use and consistently high image quality to successfully implement autonomous AI diagnostics in the front lines of care cannot be stressed enough,” said Michael D. Abramoff, MD, PhD, founder and CEO of IDx. “Topcon is truly the innovative market leader in developing highly automated, consistent and easy to use retinal imaging systems. Together we can prevent visual loss and blindness by ensuring the safety, accessibility, and affordability of early disease detection.”Both companies have a history of innovation. IDx received FDA clearance for IDx-DR in April 2018, marking the first time the FDA has cleared an autonomous AI diagnostic system that does not require a physician to interpret images or results. Topcon introduced the first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems and more recently announced the widely successful Maestro and Triton OCTs.“Our partnership with IDx further solidifies our position as a pioneer in the eye care business,” said Fumio Ohue, Managing Executive Officer of Topcon. “Our efforts to deliver better workflow solutions, imaging technology, and AI tools to eye care providers will be complemented by our work with IDx to bring autonomous diagnostics to a growing population of people with diabetes.”The recent FDA clearance of IDx-DR followed a clinical trial that demonstrated the autonomous AI system’s ability to safely deliver specialty-level diagnostics in primary care settings. Novice operators received minimal training on how to capture images using the Topcon NW400 and IDx-DR’s image quality AI. They successfully produced a diagnostic result 96% of the time by consistently capturing the high-quality images needed for IDx-DR to make a disease assessment.Topcon recently announced the release and class II clearance of Topcon Harmony, a diagnostic data management application with vendor-neutral connectivity that enables software providers like IDx, EHRs and third-party manufacturers to seamlessly integrate diagnostic results into one central location for eye care providers.About IDxIDx is a leading AI diagnostics company on a mission to transform the quality, accessibility, and affordability of healthcare. Founded in 2010 by a team of world-renowned clinician scientists, the company is focused on developing clinically-aligned autonomous algorithms that detect disease in medical images. By enabling diagnostic assessment in primary care settings, IDx aims to increase patient access to high-quality, affordable disease detection.The company’s first product, IDx-DR, is an FDA-cleared AI-based diagnostic system designed for use at the front lines of care to detect diabetic retinopathy. IDx-DR is intended for use by health care providers to automatically detect more than mild diabetic retinopathy in adults (22 years of age or older) diagnosed with diabetes who have not been previously diagnosed with diabetic retinopathy. IDx-DR is indicated for use with the Topcon NW400, an easy to use and highly accurate robotic fundus camera.IDx is developing additional AI-based diagnostic systems for the detection of macular degeneration, glaucoma, Alzheimer’s disease, cardiovascular disease, and stroke risk. Prior to this current round, IDx had been funded by a group of private angel investors since the company’s founding in 2010.About TopconTopcon is a comprehensive ophthalmic device manufacturer within the worldwide ophthalmic community. It introduced the world’s first commercial back-of-the-eye spectral domain (SD) and swept source (SS) optical coherence tomography (OCT) systems, which have driven innovation in eye-care.More recently, Topcon Healthcare Solutions started to enhance not only its hardware but also its software solutions. To become the leader in diagnostic software, Topcon has developed a new strategic division whose primary objective is to create world-class software solutions for the eye-care industry and beyond. The company’s products enable the collection and visualization of a wide range of imaging and clinical data while providing quantitative and clinical analysis capabilities.Topcon’s software gives clinicians access to patient exam data captured from OCTs, Visual Fields, Fundus cameras, and other Topcon and third-party devices. Topcon leverages its image management software called Synergy, where practitioners gain access to DICOM and non-DICOM information stored in a central, cloud-based environment. Additionally, Topcon now provides an integrated service that connects practitioners to an extensive network of reading services to assist in the management of sight-threatening eye diseases.IDx2300 Oakdale BlvdCoralville, IA 52241Phone: 319-248-5620www.eyediagnosis.net

  • Topcon acquires KIDE Clinical Systems, a leading optical and ophthalmology software provider

    Acquisition combines the most advanced optical and ophthalmology cloud solution provider in the market with Topcon healthcare solutions - world leader in eye care technology industry.TOKYO, Japan - April 4, 2018 - Topcon Corporation announced that Topcon Healthcare Solutions, a subsidiary in the U.S., has acquired all the outstanding shares of KIDE Clinical Systems Oy, a recognized technology leader in optical and ophthalmology cloud solutions.KIDE Clinical Systems’ Optoflow, a digital imaging solution software, connects eye care devices to produce their data automatically to KIDE Cloud where hospital grade tools are provided for diagnostic work and telemedicine. The cloud enables digital, time and place independent workflow for optical chain and eye hospitals.Further on Topcon strengthens its position in Europe as KIDE Clinical Systems becomes its research and development center for eye care cloud solutions.“Cutting Edge data management cloud based solution is an important component for screening and prognostic management service.” commented by Akifumi Baba, the president of Topcon Healthcare Solutions. “Combining KIDE Clinical Systems’ modern technology with our strong hardware, we believe we can provide advanced solution to all eye care professionals and strength our position in eye care industry”.“We’re excited to join the Topcon family,” said Anssi Ylimaula, co-founder and CEO of KIDE Clinical Systems. “Combining Optoflow with Topcon devices will create something never seen in the medical imaging market before. With Topcon sales and financial resources we can give our customers significant leverage in their own business.”“We’ve spent the last few months with the Topcon team harmonizing and honing our joint strategy. We are excited to be bringing these technological advances to the healthcare industry as part of the Topcon team,” said Ylimaula.